ATLASRoyalty Pharma (RPRX) Q3 2026 earnings results
Royalty Pharma (RPRX) reported EPS of $1.21 against an analyst estimate of $1.18: a beat of $0.03 (2.5%). The quarter ended Sep 30, 2026; the company reported on Wednesday, November 4, 2026, before the open.
Status: Confirmed · 14:37 ET, Nov 4 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Royalty Pharma reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountRPRX Q3 2026 results at a glance
| EPS reported | $1.21 |
|---|---|
| EPS estimate | $1.18 |
| Surprise | Beat · +$0.03 (+2.5%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 4, 2026, before the open |
| Status | Confirmed · 14:37 ET, Nov 4 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Royalty Pharma’s Q3 2026, a calendar-year company.
Royalty Pharma EPS surprise history: last 4 quarters
Royalty Pharma beat the EPS estimate in 4 of its last 4 reports, with an average surprise of +6.8%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.18 | $1.21 | +2.5% | Beat | – |
| Aug 5, 2026 | $1.27 | $1.32 | +3.9% | Beat | -0.4% |
| May 6, 2026 | $1.18 | $1.30 | +10.2% | Beat | -0.5% |
| Feb 11, 2026 | $1.33 | $1.47 | +10.5% | Beat | +1.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
RPRX stock reaction to the report
The price reaction will be added after the Nov 4, 2026 close.
This section appears once a post-report closing price exists and updates with every new close.
Next RPRX earnings report
Royalty Pharma has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the RPRX earnings calendar.
ATLAS fair value and signal for RPRX
| Last price | $65.90 (-0.8%) |
|---|---|
| ATLAS fair value | $44.81 (range $36.27–$54.80) · price is 47% above it |
| Chance of a higher close in 1 month | 52% (normal range $63.39–$68.97) |
These are model outputs from the same valuation and calibrated model as the Royalty Pharma stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Royalty Pharma Q3 2026 earnings: frequently asked questions
Did Royalty Pharma beat earnings estimates for Q3 2026?
Royalty Pharma reported EPS of $1.21 against an analyst estimate of $1.18: a beat of $0.03 (2.5%).
When did Royalty Pharma report Q3 2026 results?
Royalty Pharma reported on Wednesday, November 4, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does RPRX beat EPS estimates?
In its last 4 reports with a recorded result, Royalty Pharma beat the EPS estimate 4 times; the average surprise was +6.8%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer